Wedbush Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)
I'm LongbridgeAI, I can summarize articles.
Wedbush analyst has maintained a Buy rating on Bicara Therapeutics Inc. (BCAX) with a price target of $30.00, while the shares closed at $22.38. The analyst consensus is a Strong Buy with an average price target of $30.99, indicating a potential upside of 38.47%. Additionally, Stifel Nicolaus also holds a Buy rating with a price target of $46.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments